CA3021571C - Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors - Google Patents

Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors Download PDF

Info

Publication number
CA3021571C
CA3021571C CA3021571A CA3021571A CA3021571C CA 3021571 C CA3021571 C CA 3021571C CA 3021571 A CA3021571 A CA 3021571A CA 3021571 A CA3021571 A CA 3021571A CA 3021571 C CA3021571 C CA 3021571C
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
alkyl
nad
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3021571A
Other languages
English (en)
French (fr)
Other versions
CA3021571A1 (en
Inventor
Ryan DELLINGER
Troy Rhonemus
Mark Morris
Aron Erickson
Hadi Cassier
Marie E. Migaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chromadex Inc
Original Assignee
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc filed Critical Chromadex Inc
Publication of CA3021571A1 publication Critical patent/CA3021571A1/en
Application granted granted Critical
Publication of CA3021571C publication Critical patent/CA3021571C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
CA3021571A 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors Active CA3021571C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662325264P 2016-04-20 2016-04-20
US62/325,264 2016-04-20
PCT/US2017/028673 WO2017184885A1 (en) 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors

Publications (2)

Publication Number Publication Date
CA3021571A1 CA3021571A1 (en) 2017-10-26
CA3021571C true CA3021571C (en) 2023-01-03

Family

ID=60088650

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3021571A Active CA3021571C (en) 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors

Country Status (13)

Country Link
US (1) US10183036B2 (https=)
EP (1) EP3445359B8 (https=)
JP (3) JP7089480B2 (https=)
KR (1) KR20190008246A (https=)
CN (1) CN109640984A (https=)
AU (2) AU2017254657A1 (https=)
BR (1) BR112018071573A2 (https=)
CA (1) CA3021571C (https=)
ES (1) ES2948968T3 (https=)
MX (1) MX393076B (https=)
NZ (1) NZ747693A (https=)
WO (1) WO2017184885A1 (https=)
ZA (1) ZA201807736B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011788A1 (en) * 2015-07-15 2017-01-19 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
JP6949002B6 (ja) 2015-08-05 2021-11-17 メトロ インターナショナル バイオテック，エルエルシー ニコチンアミドモノヌクレオチド誘導体及びそれらの使用
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CA3045876A1 (en) 2016-11-11 2018-05-17 The Queen's University Of Belfast Scalable syntheses of nicotinoyl ribosides and reduced nic otinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
MX2019006278A (es) 2016-11-29 2019-08-21 Univ Iowa Res Found Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia.
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
WO2018191771A1 (en) * 2017-04-18 2018-10-25 Victor Chang Cardiac Research Institute Detection and treatment of congenital malformations
EP3642214A2 (en) 2017-06-19 2020-04-29 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
US11180521B2 (en) 2018-01-30 2021-11-23 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
KR20260020496A (ko) * 2018-05-22 2026-02-11 점프스타트 퍼틸리티 피티와이 엘티디 노화방지제로서의 니코틴산 리보사이드의 아미노산 염
EP3897666A2 (en) 2018-12-17 2021-10-27 Mitopower LLC Nicotinyl riboside compounds and their uses
KR20220013540A (ko) 2019-02-21 2022-02-04 크로마덱스 아이엔씨. 니코틴아미드 리보사이드, 니코틴산 리보사이드, 환원 니코티닐 리보사이드 화합물, 및 니코티닐 리보사이드 화합물 유도체의 제형에서의 용도
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
CA3139615A1 (en) * 2019-06-05 2020-12-10 Societe Des Produits Nestle S.A. Reduced nicotinamideribosides for the treatment/prevention of liver disease
WO2020245187A1 (en) * 2019-06-05 2020-12-10 Société des Produits Nestlé S.A. Reduced nicotinamideribosides for treating or preventing kidney disease
AU2020287733A1 (en) * 2019-06-05 2021-11-04 Société des Produits Nestlé S.A. Reduced nicotinamideribosides for treating/preventing skeletal muscle disease
CN110973260A (zh) * 2019-12-11 2020-04-10 杨力 一种含有烟酰胺核糖苷的牛奶及其制备方法与应用
WO2021123245A1 (en) 2019-12-19 2021-06-24 Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) Nad-precursors and dietary restriction for treating age-related medical conditions
EP4117680A1 (en) * 2020-03-09 2023-01-18 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of lung diseases and conditions
US20230114280A1 (en) * 2020-03-09 2023-04-13 Societe Des Produits Nestle S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions
US20230138327A1 (en) * 2020-03-09 2023-05-04 Societe Des Produits Nestle S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions
WO2021180731A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions
CN114561342B (zh) * 2020-11-27 2024-12-20 西安交通大学医学院第一附属医院 Nad信号通路激动剂在体外胚胎培养中的应用
CN115669929A (zh) * 2021-01-15 2023-02-03 江苏恒正合生命科学有限公司 辅助改善记忆的功能性食品其制备方法
WO2022233625A2 (en) * 2021-05-05 2022-11-10 Société des Produits Nestlé S.A. Composition and methods using combination of narh and nr to produce intracellular nicotinamide adenine dinucleotide (nad+)
WO2022251491A1 (en) 2021-05-27 2022-12-01 Metro International Biotech, Llc Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use
EP4313067A4 (en) * 2021-06-18 2024-12-18 Mitopower LLC TREATMENT OF IMMUNITY-RELATED DISORDERS, RENAL DISORDERS, LIVER DISORDERS, HEMOLYTIC DISORDERS AND OXIDATIVE STRESS-RELATED DISORDERS USING NRH, NARH AND THEIR REDUCED DERIVATIVES
JP7111878B1 (ja) 2021-10-27 2022-08-02 旭化成ファーマ株式会社 ニコチンアミドモノヌクレオチドの製造方法
CN118176006A (zh) * 2021-10-27 2024-06-11 益力舒健康公司 治疗更年期综合征的方法
WO2023150072A1 (en) 2022-02-01 2023-08-10 Sinclair David A Compositions and methods for the preservation of plant matter
JP2025505177A (ja) * 2022-02-04 2025-02-21 エリジウム ヘルス インコーポレーテッド リボースリンカーおよびその複合体
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022680B2 (en) * 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7927859B2 (en) * 2003-08-22 2011-04-19 Rice University High molar succinate yield bacteria by increasing the intracellular NADH availability
EP1723227A4 (en) 2004-02-10 2007-09-19 Dartmouth College NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE
CN1964627B (zh) 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
CN101360421B (zh) * 2005-11-18 2014-06-18 康乃尔研究基金会有限公司 烟酰核苷组合物及其使用方法
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
CA2928656C (en) 2013-10-30 2020-07-28 ChromaDex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
CA2951287A1 (en) * 2014-06-06 2015-12-10 Glaxosmithkline Intellectual Property (No. 2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
CN107531738B (zh) * 2015-03-16 2021-02-19 可劳迈戴斯有限公司 烟酸核苷或烟酰胺核苷组合物、其还原衍生物及其用途
WO2017011788A1 (en) 2015-07-15 2017-01-19 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
JP6949002B6 (ja) 2015-08-05 2021-11-17 メトロ インターナショナル バイオテック，エルエルシー ニコチンアミドモノヌクレオチド誘導体及びそれらの使用
CN115176998A (zh) * 2016-04-14 2022-10-14 可劳迈戴斯有限公司 烟酰胺核苷、烟酸核苷、烟酰胺单核苷酸和烟碱基化合物衍生物在婴儿配方中的用途

Also Published As

Publication number Publication date
KR20190008246A (ko) 2019-01-23
ES2948968T3 (es) 2023-09-22
MX393076B (es) 2025-03-24
AU2017254657A1 (en) 2018-11-15
JP2021176871A (ja) 2021-11-11
BR112018071573A2 (pt) 2019-02-12
AU2022221384A1 (en) 2022-09-22
EP3445359A4 (en) 2019-12-25
MX2018012849A (es) 2019-08-29
EP3445359B8 (en) 2023-09-06
CN109640984A (zh) 2019-04-16
AU2022221384B2 (en) 2023-03-23
WO2017184885A8 (en) 2023-08-24
JP2023002685A (ja) 2023-01-10
WO2017184885A1 (en) 2017-10-26
EP3445359C0 (en) 2023-06-07
EP3445359B1 (en) 2023-06-07
ZA201807736B (en) 2020-05-27
JP2019514874A (ja) 2019-06-06
CA3021571A1 (en) 2017-10-26
AU2022221384C1 (en) 2023-08-03
JP7493007B2 (ja) 2024-05-30
EP3445359A1 (en) 2019-02-27
US10183036B2 (en) 2019-01-22
NZ747693A (en) 2023-07-28
US20170304338A1 (en) 2017-10-26
JP7089480B2 (ja) 2022-06-22

Similar Documents

Publication Publication Date Title
AU2022221384B2 (en) Use of Nicotinic acid Riboside or Nicotinamide Ribosite derivatives, and reduced derivatives thereof, as nad+ increasing precursors
US12433908B2 (en) Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development
US10934322B2 (en) B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
AU2020224158B2 (en) Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivatives in formulations
AU2019214858B2 (en) Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
CA2696878A1 (en) Compositions and methods for treatment of mitochondrial diseases
HK40004710A (en) Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors
US20230295211A1 (en) Methods of producing crystalline beta nicotinamide riboside triacetate chloride

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201113

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250411

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250411